by the transplant team. 7 Such decision making may also be biased by recent clinical experiences, which may disproportionally impact clinician recommendations. Conflicts between transplant and nontransplant health care professionals, within the transplant team, or between patients and family members and care teams as to whether ongoing treatment is medically futile or likely futile can be difficult to navigate.
There are few studies investigating length of stay (LOS) and subsequent survival to discharge. There are also limited data on postdischarge mortality among patients who survive a prolonged initial hospitalization. This information is essential to an informed discussion when there is conflict over continuing life-sustaining treatment in transplant recipients with prolonged initial hospitalizations. The primary objective of this project was to use the United Network for
Organ Sharing Scientific Registry of Transplant Recipients (SRTR)
database to identify thresholds of length of initial hospitalization beyond which subsequent survival to discharge is uniformly poor. The secondary objective was to identify mortality rates and predictors of subsequent 1, 3, and 5 year mortality, defined as death or graft failure, among patients with prolonged hospitalizations who are successfully discharged.
| ME THODS
This study utilized data from SRTR, which includes information on all donors, waitlisted candidates, and transplant recipients in the 
| Clinical and sociodemographic variables

| Outcomes
We recorded length of index hospitalization and patient status (alive vs deceased) at the time of discharge. We also calculated time from initial discharge to death or allograft failure (as a composite endpoint) or last status update (if alive).
| Statistical analysis
For each day of the index hospitalization we calculated the mor- Patients missing data were excluded from specific calculations (Table S1 ).
All analyses were performed using Stata (Version 15.1, Stata
Corp, College Station, TX). The Massachusetts General Hospital
Institutional Review Board approved this study. 
| RE SULTS
| Study cohort
| Index hospitalization mortality
The overall index hospitalization mortality was 5.4%. In-hospital mortality initially increased for each day that recipients survived Risk factors for index hospitalization mortality are listed in Figure 1 ).
| Postdischarge survival
In order to assess the impact of initial hospitalization LOS on post-discharge survival, we defined prolonged LOS by the 97th percentile or higher LOS (>90 days). among those >65, White recipients, and single lung transplants, respectively (Table S2 ).
| D ISCUSS I ON
The care of lung transplant patients with prolonged initial hospitalizations can be ethically complex, particularly when there is disagreement over whether ongoing intensive treatment is warranted.
The aim of this study was to add empirical information to these discussions, particularly about expected survival to hospital discharge and over the subsequent 5 years. Our primary findings were that:
(a) although increased LOS was associated with decreased survival following lung transplant, in-hospital morality rarely exceeded 50%, even for patients with very prolonged LOS; (b) long-term survival among patients with LOS>90 days remains significantly worse than other recipients, particularly those over age 65.
Prior studies in lung transplant recipients have identified LOS as a risk factor for index hospitalization and postdischarge mortality. Rather than simply identifying a factor such as dialysis as placing the patient generally "at risk" for in-hospital mortality, knowing, for example, that 60% of dialysis-requiring patients who have survived for 90 days leave the hospital alive is a more concrete way of framing the decision to continue or withdraw life-sustaining treatment (Table S2) .
Importantly, although we did not find time points where subsequent index hospitalization mortality was consistently above 50%, there were some combinations of factors (e.g. posttransplant stroke
and airway dehiscence and dialysis dependence) that were so infrequent as to prevent meaningful calculation of survival to discharge.
There is, likely an accumulation of deficits beyond which survival is uniformly poor and our results should not be interpreted as suggesting that life-sustaining treatment is always justified during the initial posttransplant hospitalization. Our data demonstrating that survival to discharge is at least 50% even in lung transplant recipients with F I G U R E 1 Subsequent in-hospital mortality rate for lung transplant recipients by length of hospital stay. Cohort broken down by all recipients, recipients requiring posttransplant dialysis, and recipients with posttransplant stroke, the two largest risk factors for index hospitalization mortality. Italicized numbers reflect the number of recipients still hospitalized at a specific time point index LOS >90 days may help inform discussions with families and providers. These data may also help transplant providers avoid overreliance on anecdotal experience, which can color such discussions.
In previous studies regarding patient and surrogate preferences to continue life-sustaining treatment, the majority indicated that they would want to continue interventions unless the predicted likelihood of survival falls below 10%-20%. 12 Focus on near-term survival, however, is only one aspect of achieving a successful posttransplant outcome and we believe that a highquality goals of care conversation for recipients with prolonged hospitalizations must also include information on longer-term outcomes. In this regard, we found that recipients with prolonged hospitalization had worse 1, 3, and 5 year survival. Although single-center studies have reported no differences in survival for recipients with prolonged hospitalization, our findings are similar to another large analysis of SRTR data that used >25 days as a prolonged LOS cutoff. 1, 2 As in that study, we found that using different LOS thresholds (>70 days, >90 days, >150 days) did not change the association with longer-term mortality, suggesting that LOS is a marker for poor long-term postdischarge survival. Because survival-following-discharge models do not account for the duration of time already spent in the hospital among recipients with a prolonged course, they are subject to lead-time bias. It is, therefore, important to note that our analysis does not apply to discussions regarding the relationship between LOS and overall posttransplant survival, only postdischarge survival.
For recipients above age 65 with a prolonged hospitalization >90 days, it is important to acknowledge that, although the chance of survival to discharge may exceed 50%, the expected mortality in the next year following discharge remains high. Particularly in cases where recipients have accumulated significant functional deficits that are not compatible with the patients' expectations for meaningful posttransplant quality of life, it may be reasonable to limit life-sustaining treatment during the index hospitalization. This is particularly true if the expected survival is not acceptable to the patient and/or his or her surrogate. In these situations, a multidisciplinary meeting including the patient and surrogate(s), medical and surgical transplant team members, other involved health care professionals including bedside and nursing leadership and, where appropriate, palliative care or ethics consultants, is essential to successful communication and shared decision-making. 13 The fact that very few variables in SRTR were associated with subsequent mortality in patients with prolonged hospitalization suggests that there are other relevant, uncaptured predictors. Information, for example, on frailty at transplant or discharge would potentially be of interest given the association between frailty and posttransplant mortality. and it is likely that many recipients with prolonged lengths of stay are discharged to other facilities. 15 We do not know what percentage of these patients are eventually able to return to independent or semi-independent living in the community. Although Karnofsky performance status is included in SRTR, very few patients with prolonged hospitalization had this variable recorded and it is a poor substitute for more detailed health-related quality of life assessments.
Such measurements would be extremely helpful in discussing the expected outcomes associated with ongoing intensive interventions. 16 As several studies have suggested, patients and providers often assume better long-term quality of life and functional outcomes than actually occur among survivors of critical illness with a prolonged hospitalization.
17,18
| LI M ITATI O N S
In addition to lack of information on disposition and long-term quality of life measures, our study has several other limitations. First, although we used a large national database, coding practices vary between individual centers and there were some data missing for most predictor and outcome variable. In addition, SRTR does not include specific dates for the occurrence of time-dependent post-operative events such as initiation of dialysis. Based on the available literature, by day 90 patients have typically experienced the relevant index hospitalization adverse event (stroke, dialysis, airway dehiscence). Survival to discharge calculations are, therefore, more likely to be relevant to patients with longer exposure time. 4, 5, 9, 10 In addition, because there was no mechanism to identify when the exposure occurred during the hospitalization it is possible that events such as need for dialysis or stroke are a marker for some other process that, itself, is driving mortality. TA B L E 3 Risk factors for subsequent post-discharge mortality among lung transplant recipients with a prolonged (>90 day) initial hospitalization (N = 405) and in no way should be seen as an official policy of or interpretation by the SRTR or the U.S. Government.
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